6-K filed Sep 1, 2026 at 06:21 ET
Novartis announced positive Phase III topline results for remibrutinib in relapsing multiple sclerosis (RMS). The REMODEL-1 and REMODEL-2 trials met their primary endpoint of significantly reducing annualized relapse rate (ARR) versus teriflunomide, with superiority on all key secondary endpoints including MRI lesions and disability progression. The safety profile was favorable with no liver safety signal. Novartis plans to present the data at MSToronto2026 and seek global regulatory approval. This expands remibrutinib's pipeline beyond its already-approved CSU indication (Rhapsido), representing a significant pipeline catalyst for a large-market indication (RMS affects nearly 3 million people worldwide). No financial figures were provided in the filing.